Prenatal Cell‐Free DNA Screening With Fetal Enrichment Enables Sampling From 8 Weeks of Gestational Age
Clinical Genetics · 2026
DOI: 10.1111/cge.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Seyedeh Saideh Daryabari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Axe SPPOS, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, Quebec, Canada. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Prenatal Diagnosis, Noninvasive Prenatal Testing. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: La Fondation de l'Université Laval - Fonds de recherche St-Francois-d'Assise, La Fondation de l'Université Laval - Chaire de recherche Jeanne et J.-Louis Lévesque, Génome Québec.
Abstract (Originalsprache)
Cell‐free DNA (cfDNA) screening for fetal aneuploidy is typically offered from 10 weeks of gestational age (GA) onward. Fetal fraction (FF) enrichment may enable screening before 10 weeks with a low failure rate. This study aimed to assess the feasibility of cfDNA screening with in vitro enrichment before 10 weeks of gestation. 435 pregnant women were recruited between 7w0d and 9w6d of GA (EARLY samples) and scheduled for a second cfDNA sample after 11 weeks of GA (12w+ samples). 371 women provided both an EARLY and a 12w+ sample, and we compared cfDNA results between EARLY and 12w+ samples and sex at birth. For sex determination using cfDNA, EARLY, and 12w+ samples were 100% concordant with clinical sex at birth. In 170 male pregnancies, EARLY samples 5.9% had FF < 4% after enrichment. Seven aneuploidies were observed early, but eight at 12+ weeks (one false positive after invasive diagnostic testing). We observed 4.4% spontaneous abortions between the EARLY and 12w+ sampling. Our findings suggest that in vitro fetal enrichment provides sufficient cfDNA for reliable prenatal cfDNA screening results as early as 8 weeks, but one limitation lies in the high proportion of spontaneous abortions before 12w0d.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Axe SPPOS, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, Quebec, Canada.
- Department of Laboratory Medicine, CHU de Québec, Hôpital St-François D'Assise, Quebec city, Quebec, Canada.
- Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Obstetrics and Gynecology, Université Laval and CHU de Québec, Quebec City, Quebec, Canada.
ORCID-Profile: Seyedeh Saideh Daryabari, André Caron, Jean-Claude Forest, Sylvie Langlois, Emmanuel Bujold, François Rousseau
Förderung
- La Fondation de l'Université Laval - Fonds de recherche St-Francois-d'Assise
- La Fondation de l'Université Laval - Chaire de recherche Jeanne et J.-Louis Lévesque
- Génome Québec
Zitieren
APA
Daryabari, S. S., Giroux, S., Caron, A., Forest, J. C., Langlois, S., Bujold, E., & Rousseau, F. (2026). Prenatal Cell‐Free DNA Screening With Fetal Enrichment Enables Sampling From 8 Weeks of Gestational Age. Clinical Genetics. https://doi.org/10.1111/cge.70020
Vancouver
Daryabari SS, Giroux S, Caron A, Forest JC, Langlois S, Bujold E, et al. Prenatal Cell‐Free DNA Screening With Fetal Enrichment Enables Sampling From 8 Weeks of Gestational Age. Clinical Genetics. 2026. doi:10.1111/cge.70020
BibTeX
@article{Daryabari2026,
author = {Daryabari, Seyedeh Saideh and Giroux, Sylvie and Caron, André and Forest, Jean-Claude and Langlois, Sylvie and Bujold, Emmanuel and Rousseau, François},
title = {Prenatal Cell‐Free DNA Screening With Fetal Enrichment Enables Sampling From 8 Weeks of Gestational Age},
journal = {Clinical Genetics},
year = {2026},
doi = {10.1111/cge.70020}
}
EUVIMED